Načítá se...
Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery
Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of...
Uloženo v:
| Vydáno v: | Pharmaceuticals (Basel) |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7697739/ https://ncbi.nlm.nih.gov/pubmed/33207605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110394 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|